
Opinion|Videos|December 8, 2023
Treatment Landscape in ER+/HER2- Metastatic Breast Cancer and Unmet Needs
Author(s)Joyce O'Shaughnessy, MD
A discussion of the disease state, current therapies, and treatment challenges in ER+/HER2- metastatic breast cancer.
Advertisement
Episodes in this series

Now Playing
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5











































